SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,761,741 | -27.9% | 121,332 | +4.0% | 0.00% | -50.0% |
| Q2 2023 | $2,442,782 | -81.4% | 116,712 | -81.2% | 0.00% | -75.0% |
| Q1 2023 | $13,098,941 | +93.5% | 620,215 | +133.2% | 0.01% | +60.0% |
| Q4 2022 | $6,767,995 | -47.0% | 265,933 | -49.9% | 0.01% | -44.4% |
| Q3 2022 | $12,759,000 | +42.9% | 530,986 | +14.4% | 0.01% | +28.6% |
| Q2 2022 | $8,927,000 | +2020.4% | 463,979 | +1818.4% | 0.01% | – |
| Q1 2022 | $421,000 | -85.2% | 24,186 | -81.4% | 0.00% | -100.0% |
| Q4 2021 | $2,848,000 | +175.7% | 130,087 | +140.6% | 0.00% | +100.0% |
| Q3 2021 | $1,033,000 | -71.8% | 54,064 | -74.7% | 0.00% | -50.0% |
| Q2 2021 | $3,663,000 | -9.1% | 213,360 | +18.3% | 0.00% | -33.3% |
| Q1 2021 | $4,031,000 | +2500.6% | 180,294 | +2481.5% | 0.00% | – |
| Q4 2020 | $155,000 | +604.5% | 6,984 | +363.1% | 0.00% | – |
| Q3 2020 | $22,000 | -96.8% | 1,508 | -96.7% | 0.00% | -100.0% |
| Q2 2020 | $687,000 | +1045.0% | 46,375 | +742.7% | 0.00% | – |
| Q1 2020 | $60,000 | +66.7% | 5,503 | +32.9% | 0.00% | – |
| Q4 2019 | $36,000 | +111.8% | 4,141 | +88.7% | 0.00% | – |
| Q3 2019 | $17,000 | -67.3% | 2,194 | -61.0% | 0.00% | – |
| Q2 2019 | $52,000 | +126.1% | 5,632 | +30.0% | 0.00% | – |
| Q1 2019 | $23,000 | +21.1% | 4,333 | +2.6% | 0.00% | – |
| Q4 2018 | $19,000 | -89.9% | 4,225 | -81.8% | 0.00% | – |
| Q3 2018 | $188,000 | +291.7% | 23,191 | +241.0% | 0.00% | – |
| Q2 2018 | $48,000 | +60.0% | 6,800 | +219.8% | 0.00% | – |
| Q1 2018 | $30,000 | +1400.0% | 2,126 | +1024.9% | 0.00% | – |
| Q4 2017 | $2,000 | +100.0% | 189 | +101.1% | 0.00% | – |
| Q2 2017 | $1,000 | -50.0% | 94 | -25.4% | 0.00% | – |
| Q1 2017 | $2,000 | – | 126 | +3050.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 4 | -99.0% | 0.00% | – |
| Q3 2016 | $6,000 | +20.0% | 384 | -18.5% | 0.00% | – |
| Q2 2016 | $5,000 | – | 471 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |